Deals in Depth: January 2010

Article preview reprinted from IN VIVO -  February/March, 2010

Alliance dollars were low in January, with only three biopharma deals reaching a potential deal value of $100 million or more, led by Ipsen and Inspiration's collaboration in hemophilia, worth $518 million. The bigger M&A dollars were seen in the device and diagnostic sectors, including Medtronic's take-out of CV device firm Invatec and its affiliates for $500 million. Both biopharma and device financing were down compared with December. Read more...

Deals in Depth: January 2010

Article preview reprinted from IN VIVO -  February/March, 2010

Our monthly overview of dealmaking in the biopharmaceutical, medical device and in vitro diagnostics industries.

January 2010 dealmaking highlights:

Alliance dollars were low in January, with only three biopharma deals reaching a potential deal value of $100 million or more. Leading those was Ipsen and Inspiration's collaboration in hemophilia, worth $518 million.

The bigger M&A dollars were seen in the device and diagnostic sectors. Medtronic paid $500 million for CV device firm Invatec and its affiliates. Meanwhile Inverness did a pair of $200 million-plus takeovers—POC tester and partner Epocal and the partial acquisition of Korean company Standard Diagnostics. Both biopharma and device financing were down compared with December. Once again, money from follow-ons, particularly the financing from AMAG, fueled the total invested in drug companies.

- Amanda Micklus

Purchase this article online  as a PDF and receive it immediately via email. Questions? Call (800) 332-2181. 100% Satisfaction Guaranteed.

Medical device manufacturers facing many challenges: from the rising clout of group purchasing organizations (GPOs) to payment bundling and physicians' growing allegiance with hospitals in product price negotiations. Get all the answers now in new Medtech Insight's new 24-page Special Report: Medical Device Landscape: How regulatory changes and cost control measures are reshaping the industry. Availible for purchase now!

Limited-time offer: Single-incision laparoscopy or natural orifice surgery: Which will win the day, or is there room for both? Are You Ready For The New Scarless Surgery Revolution? Download you FREE report now

Companies mentioned in this article

Digital Biotech Co. Ltd.

Epocal Inc.

Inspiration Biopharmaceuticals Inc.

International Vitamin Corp.

Inverness Medical Nutritionals Group

Inverness Medical Innovations Inc.

Standard Diagnostics Inc.

Ipsen

Johnson & Johnson

LifeScan Inc.

Animas Corp.

Juvenile Diabetes Research Foundation

Kirin Holdings Co. Ltd.

Kyowa Hakko Kirin Co. Ltd.

Krauth medical KG

Martek Biosciences Corp.

Amerifit Brands Inc.

Medtronic Inc.

Invatec SRL

Krauth Cardiovascular GMBH

Merz GMBH & Co. KGAA

Merz Aesthetics US

Merz Pharmaceuticals GMBH

Quidel Corp.

Diagnostic Hybrids Inc.

Reata Pharmaceuticals Inc.

Roche

Sonova Holding AG

InSound Medical Inc.

Subscribe to IN VIVO.

IN VIVO delivers:

• Revealing, in-depth coverage of your competitors' strategies
• Incisive projections of future industry trends and their implications for your business
• Expert analysis of key industry developments
• Exclusive interviews with top industry executives and analysts
• In-depth examination of dealmaking, marketing, R&D, regulatory, and finance strategies -- those that were successful and those that missed the mark